TScan Therapeutics TCRX Stock
TScan Therapeutics Price Chart
TScan Therapeutics TCRX Financial and Trading Overview
| TScan Therapeutics stock price | 0.97 USD |
| Previous Close | 1.08 USD |
| Open | 1.08 USD |
| Bid | 0.76 USD x 200 |
| Ask | 1.3 USD x 200 |
| Day's Range | 1.01 - 1.08 USD |
| 52 Week Range | 0.88 - 2.57 USD |
| Volume | 478.72K USD |
| Avg. Volume | 867.48K USD |
| Market Cap | 66M USD |
| Beta (5Y Monthly) | 1.063 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.96 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6 USD |
TCRX Valuation Measures
| Enterprise Value | 30.48M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.1380281 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.2246413 |
| Price/Book (mrq) | 0.46672827 |
| Enterprise Value/Revenue | 3.337 |
| Enterprise Value/EBITDA | -0.246 |
Trading Information
TScan Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.063 |
| 52-Week Change | -42.28% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 2.57 USD |
| 52 Week Low | 0.88 USD |
| 50-Day Moving Average | 1.11 USD |
| 200-Day Moving Average | 1.32 USD |
TCRX Share Statistics
| Avg. Volume (3 month) | 867.48K USD |
| Avg. Daily Volume (10-Days) | 461.67K USD |
| Shares Outstanding | 61.07M |
| Float | 55.39M |
| Short Ratio | 0.9 |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 59.47% |
| Shares Short | 876.56K |
| Short % of Float | 1.95% |
| Short % of Shares Outstanding | 1.34% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2967.31% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -29.62% |
| Return on Equity (ttm) | -80.94% |
Income Statement
| Revenue (ttm) | 9.14M USD |
| Revenue Per Share (ttm) | 0.15 USD |
| Quarterly Revenue Growth (yoy) | -54.80% |
| Gross Profit (ttm) | -95530000 USD |
| EBITDA | -123821000 USD |
| Net Income Avi to Common (ttm) | -124305000 USD |
| Diluted EPS (ttm) | -0.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 128.06M USD |
| Total Cash Per Share (mrq) | 1.96 USD |
| Total Debt (mrq) | 92.54M USD |
| Total Debt/Equity (mrq) | 95.48 USD |
| Current Ratio (mrq) | 6.648 |
| Book Value Per Share (mrq) | 2.164 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -122012000 USD |
| Levered Free Cash Flow (ttm) | -84107624 USD |
Profile of TScan Therapeutics
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 830 Winter Street |
| ZIP | 02451 |
| Phone | 857 399 9500 |
| Website | https://www.tscan.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 138 |
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Q&A For TScan Therapeutics Stock
What is a current TCRX stock price?
TScan Therapeutics TCRX stock price today per share is 0.97 USD.
How to purchase TScan Therapeutics stock?
You can buy TCRX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for TScan Therapeutics?
The stock symbol or ticker of TScan Therapeutics is TCRX.
Which industry does the TScan Therapeutics company belong to?
The TScan Therapeutics industry is Biotechnology.
How many shares does TScan Therapeutics have in circulation?
The max supply of TScan Therapeutics shares is 65.35M.
What is TScan Therapeutics Price to Earnings Ratio (PE Ratio)?
TScan Therapeutics PE Ratio is now.
What was TScan Therapeutics earnings per share over the trailing 12 months (TTM)?
TScan Therapeutics EPS is -0.96 USD over the trailing 12 months.
Which sector does the TScan Therapeutics company belong to?
The TScan Therapeutics sector is Healthcare.
TScan Therapeutics TCRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| NYSE Composite Index NYA | 23276.49 USD — |
-0.87
|
— — | 23276.49 USD — | 23480.92 USD — | — - | — — |
- {{ link.label }} {{link}}